Complete Your Journey to Therapeutic Success
Meeting global regulatory standards for GLP-1 receptor agonists and other peptide therapeutics is increasingly complex. Agilent simplifies your journey with end-to-end characterization workflows, ease of adoption and expertise at every step.
Learn more about the following workflows:
Explore Agilent solutions.
As your total-solution partner, Agilent empowers your therapeutic peptide development journey with advanced solutions, end-to-end characterization workflows, ease of adoption, and expertise at every step.
This comprehensive resource brings together proven analytical workflows for GLP‑1 receptor agonists and other therapeutic peptides.
Gain access to expert insights, method optimization tips, and detailed workflows that streamline peptide characterization and accelerate development.
GLP-1 receptor agonists like Semaglutide and Tirzepatide are complex therapeutic peptides used in treating type 2 diabetes and obesity. Their structural complexity and formulation with diverse excipients pose significant analytical challenges. This webinar will explore impurity profiling and excipient analysis using orthogonal HILIC-UV/MS and HILIC-ELSD workflows.
Agilent supports every stage of your GLP-1 receptor agonist and peptide therapeutics development journey, from discovery to commercialization.
This in-depth guide provides a comprehensive overview of Agilent end-to-end solutions for GLP-1 receptor agonist and peptide therapeutic development.
Agilent CrossLab Services deliver more than just maintenance—they provide a strategic partnership to elevate your lab’s performance.
Empower your lab’s growth with Agilent Financial Solutions—flexible financing designed to meet the evolving needs of scientific innovation.